Compare Neurocrine Biosciences Inc (NBIX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs TG Therapeutics Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× TG Therapeutics Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | TGTX | |
|---|---|---|
Market Cap | $17.40B | $8.26B |
Sector | Health | Health |
52-Week High | $180.55 | $59.06 |
52-Week Low | $123.10 | $26.39 |
Enterprise Value | $16.49B | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
